B. Riley raised the firm’s price target on Harrow (HROW) to $74 from $70 and keeps a Buy rating on the shares following the analyst day. The firm says the company’s pipeline portfolio and commercial roadmap up its confidence in a bullish long-term revenue and margin expansion thesis for Harrow.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HROW:
- Harrow price target raised to $70 from $42 at Lake Street
- Harrow Health Secures New $40 Million Credit Facility
- Harrow Health’s Promising Growth Trajectory: Buy Rating Supported by Strategic Initiatives and Product Expansion
- Harrow Health’s Promising Growth Trajectory: Analyst Recommends ‘Buy’ Amid Strategic Revenue Projections and Product Enthusiasm
- Harrow Health Hosts Investor Day Presentation